EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Baricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients

Irini Flouri, Antonios Bertsias, Konstantina Zoupidou, Christos Koutsianas, George Fragoulis, Dimitrios Nezis-Katsifis, Elena Sambatakaki, Nestor Avgoustidis, Argyro Repa, George Bertsias, Maria Tektonidou, Petros Sfikakis und 3 weitere

Rheumatology International · 05.10.2026 · 46 (10)

DOI: 10.1007/s00296-026-06313-y ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Rheumatology International, online erschienen am 05.10.2026. Verfasst von Irini Flouri und 14 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology, Clinical Immunology, Medical School, University of Crete, Heraklion, Greece. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Azetidines, Pyrazoles, Sulfonamides. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Herein we report for baricitinib drug retention, predictors thereof and clinical responses in rheumatoid arthritis (RA) patients with a special focus in comorbidities. Prospective, multicenter, observational study of RA patients starting baricitinib because of active disease. Patients were followed every 3 months for 12 months. The primary endpoint was baricitinib retention at 12 months; predictors for survival and clinical responses at 6 months were secondary endpoints. Retention rate was estimated by Kaplan–Meier (K-M) while predictors of discontinuation by Cox regression. We recruited 135 patients, 93.3% females, mean (standard deviation-SD) age 56.1 (10.1) years, median (interquartile range) disease duration 57 (90) months. 18.5% started baricitinib as first line targeted therapy. 35.9% (28/88) and 44.1% (26/59) achieved DAS28 remission/low disease activity (LDA) at 6 and 12 months respectively. Baricitinib retention at 12 months was 68.9%. K-M analysis showed that hypertension (p=0.049), latent tuberculosis infection (LTBi) (p=0.007) and depression (p=0.005) were associated to lower retention, while multivariate analysis showed that depression [Hazard ratio (HR) 2.715, p=0.007] and LTBi (HR 2.519, p=0.020) predicted baricitinib discontinuation. Analysis for patients on therapy for at least 6 months showed that together with hypertension (HR 2.477, p=0.022) and LTBi (HR 3.761, p=0.023), higher DAS28 at 6 months (HR 1.434, p=0.024) predicted baricitinib discontinuation at 12 months. In established RA, 68.9% of the patients remained on baricitinib at 12 months and had an improvement of disease activity. Mostly comorbidities contributed to baricitinib persistence, supporting their importance as factors to be addressed to optimize RA clinical care.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidAzetidinesPyrazolesSulfonamidesAntirheumatic AgentsHumansFemaleProspective StudiesMiddle AgedPurinesMaleTreatment OutcomeAgedRemission InductionTime FactorsRisk Factors

Stichwörter der Autor:innen

ArthritisJanus kinase inhibitorsRheumatoid

Substanzen

baricitinibAzetidinesPyrazolesSulfonamidesPurinesAntirheumatic Agents

Autor:innen und Institutionen

  • Rheumatology, Clinical Immunology, Medical School, University of Crete, Heraklion, Greece.
  • Joint Rheumatology Program, 4th Department of Medicine, School of Medicine, National and Kapodistrian University of Athens, Attikon General Hospital, Athens, Greece.
  • Joint Rheumatology Program, Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, School of Medicine, National and Kapodistrian University of Athens, General Hospital of Athens 'Hippokration'…
  • Joint Academic Rheumatology Program, 1st Department of Propedeutic and Internal Medicine, National and Kapodistrian University of Greece, Athens, Greece.
  • Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece.
  • Rheumatology, Clinical Immunology, Medical School, University of Crete, Heraklion, Greece. sidiropp@uoc.gr.

Zitieren

APA

Flouri, I., Bertsias, A., Zoupidou, K., Koutsianas, C., Fragoulis, G., Nezis-Katsifis, D., Sambatakaki, E., Avgoustidis, N., Repa, A., Bertsias, G., Tektonidou, M., Sfikakis, P., Vassilopoulos, D., Boumpas, D., & Sidiropoulos, P. (2026). Baricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients. Rheumatology International, 46(10). https://doi.org/10.1007/s00296-026-06313-y

Vancouver

Flouri I, Bertsias A, Zoupidou K, Koutsianas C, Fragoulis G, Nezis-Katsifis D, et al. Baricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients. Rheumatology International. 2026;46(10). doi:10.1007/s00296-026-06313-y

BibTeX
@article{Flouri2026,
  author = {Flouri, Irini and Bertsias, Antonios and Zoupidou, Konstantina and Koutsianas, Christos and Fragoulis, George and Nezis-Katsifis, Dimitrios and Sambatakaki, Elena and Avgoustidis, Nestor and Repa, Argyro and Bertsias, George and Tektonidou, Maria and Sfikakis, Petros and Vassilopoulos, Dimitrios and Boumpas, Dimitrios and Sidiropoulos, Prodromos},
  title = {Baricitinib retention and factors associated thereof in clinical practice: a prospective, multicenter 12-month study in rheumatoid arthritis patients},
  journal = {Rheumatology International},
  year = {2026},
  volume = {46},
  number = {10},
  doi = {10.1007/s00296-026-06313-y}
}
Kostenlos starten →